Buy Terbinafine

Terbinafine

Terbinafine: Generic Medication Overview

Terbinafine is an antifungal agent available as a generic medication and marketed under brand names such as Lamisil, Exoderil, and Terbinafine-HCl. It belongs to the allylamine class of antifungals and is supplied in oral pill form, typically in a 250 mg strength. In Hong Kong, terbinafine is prescription-only and regulated by the Department of Health.

How Terbinafine Works in the Body

Terbinafine exerts its antifungal effect by inhibiting the enzyme squalene epoxidase, a key step in the sterol biosynthesis pathway of fungi. This inhibition leads to an accumulation of squalene, which is toxic to fungal cells, and a depletion of ergosterol, an essential component of the fungal cell membrane. The result is disrupted membrane integrity and fungal cell death.

• Onset of action: Clinical improvement often begins within a few days of starting therapy, although full eradication of the infection may require several weeks.
• Peak plasma concentration: Reached approximately 2-4 hours after oral administration.
• Duration of effect: Terbinafine is highly lipophilic and accumulates in skin, nails, and fatty tissue, allowing sustained antifungal activity even after the dosing period ends.

Conditions Treated by Terbinafine

Terbinafine is approved in Hong Kong for the treatment of tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete’s foot), and onychomycosis (fungal nail infection) caused by susceptible dermatophyte species. The medication is effective for both skin and nail infections, with dosing duration adjusted to the site of infection.

• Skin infections: Typically a 6-week course.
• Nail infections: Usually a 12-week course, reflecting slower nail growth and deeper fungal penetration.

Patient Suitability and Contraindications

Who Should Use Terbinafine?

• Adults with confirmed dermatophyte infection who are able to swallow oral tablets.
• Patients without significant liver disease, as terbinafine is metabolized hepatically.
• Individuals not taking medications known to interact severely with terbinafine (see interactions section).

Absolute Contraindications

• Known hypersensitivity to terbinafine or any of its excipients.
• Severe hepatic impairment (Child-Pugh Class C).
• Pregnancy (Terbinafine is classified as Category B2 in Hong Kong; use only if the potential benefit justifies the risk) and breastfeeding (caution advised).

Relative Contraindications

• Moderate hepatic impairment (monitor liver function tests).
• Renal impairment (dose adjustment may be required in severe cases).
• Concomitant use of drugs that are strong CYP2D6 substrates (e.g., certain antidepressants, antiarrhythmics) - requires monitoring.

Special Populations

• Elderly: May have reduced hepatic clearance; monitor liver enzymes.
• Pregnancy & Lactation: Discuss risks and benefits with a healthcare provider; terbinafine does cross the placenta and is excreted in breast milk.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal: Nausea, dyspepsia, abdominal pain (generally mild and transient).
• Skin: Itching, rash, or mild erythema.
• Taste disturbances: Dysgeusia or loss of taste (reported in a minority of patients).

Serious Adverse Events

• Hepatotoxicity: Elevations in ALT/AST; rare cases of severe liver injury. Prompt evaluation of liver function is recommended if symptoms such as jaundice, dark urine, or right-upper-quadrant pain develop.
• Severe skin reactions: Stevens-Johnson syndrome or toxic epidermal necrolysis (extremely rare). Discontinue immediately if widespread rash or mucosal involvement occurs.
• Blood disorders: Agranulocytosis, neutropenia, or thrombocytopenia (very uncommon).

Drug Interactions

• CYP2D6 inhibition: Terbinafine can increase plasma concentrations of drugs metabolized by CYP2D6, such as fluoxetine, paroxetine, quinidine, and certain beta-blockers. Monitoring or dose adjustment may be necessary.
• Warfarin: May potentiate anticoagulant effect; INR should be checked more frequently.
• Rifampin and carbamazepine: Enzyme inducers that can lower terbinafine levels, possibly reducing efficacy.
• Antihistamines (e.g., cetirizine), oral contraceptives: No clinically significant interaction reported, but patients should be advised to maintain routine medical review.

Food and Lifestyle Interactions

• Food: Can be taken with or without food; fatty meals may modestly increase absorption but do not require adjustment.
• Alcohol: Excessive intake may exacerbate liver toxicity; patients with liver disease should limit alcohol consumption.
• Driving: No impairment reported; however, patients experiencing dizziness or severe side effects should avoid operating machinery.

How to Take Terbinafine

• Standard dosing: One 250 mg tablet taken orally once daily.
• Duration:
• Skin infections: 6 weeks.
• Nail infections: 12 weeks (or as directed by a healthcare provider).
• Administration tips: Swallow the tablet whole with a full glass of water. No crushing or chewing is recommended.
• Missed dose: Take the missed tablet as soon as remembered on the same day; do not double the next dose.
• Overdose: Symptoms may include nausea, vomiting, abdominal pain, and dizziness. Seek emergency medical attention; supportive care is the mainstay of treatment.
• Discontinuation: No tapering is required for short courses. For prolonged therapy, follow physician guidance.

Monitoring and Follow-Up

• Baseline labs: Liver function tests (ALT, AST, bilirubin) before initiating therapy, especially in patients with pre-existing hepatic conditions.
• During treatment: Repeat liver enzymes at 4-6 weeks if treatment exceeds 6 weeks or if the patient exhibits signs of liver dysfunction.
• Clinical assessment: Evaluate infection clearance at the end of therapy; for onychomycosis, a clinical cure may be confirmed 6-12 months after treatment completion due to nail growth.

Storage and Handling

• Store tablets at room temperature (15-30 °C), protected from excessive moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use tablets beyond the expiry date printed on the packaging; discard any unused medication according to local pharmaceutical waste guidelines.

Medication-Specific Glossary

Squalene epoxidase

An enzyme in the fungal sterol synthesis pathway; inhibition by terbinafine leads to fungal cell death.

Allylamine

A class of antifungal agents that target squalene epoxidase, including terbinafine.

Onychomycosis

A fungal infection of the nail plate and matrix, often requiring prolonged systemic therapy.

Medical Disclaimer

This article provides educational information about terbinafine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.